Journal Article

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

Gaich, Carol, Rooney, Terence, Witt, Sarah, van der Heijde, Désirée, Liu, Jiajun, de la Torre, Inmaculada, Drescher, Edit, Dougados, Maxime, Chen, Ying-Chou, de Bono, Stephanie, Beattie, Scott, Greenwald, Maria, Schlichting, Douglas, Emery, Paul

2017

Overview

BackgroundBaricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor.MethodsIn this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to ≥1 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo or baricitinib (2 or 4 mg) once daily, stratified by region and the presence of joint erosions. Endpoint measures included American College of Rheumatology 20% response (ACR20, primary endpoint), Disease Activity Score (DAS28) and Simplified Disease Activity Index (SDAI) score ≤3.3.ResultsMore patients achieved ACR20 response at week 12 with baricitinib 4 mg than with placebo (62% vs 39%, p≤0.001). Compared with placebo, statistically significant improvements in DAS28, SDAI remission, Health Assessment Questionnaire-Disability Index, morning joint stiffness, worst joint pain and worst tiredness were observed. In a supportive analysis, radiographic progression of structural joint damage at week 24 was reduced with baricitinib versus placebo. Rates of adverse events during the treatment period and serious adverse events (SAEs), including serious infections, were similar among groups (SAEs: 5% for baricitinib 4 mg and placebo). One patient had an adverse event of tuberculosis (baricitinib 4 mg); one patient had an adverse event of non-melanoma skin cancer (baricitinib 4 mg). Two deaths and three major adverse cardiovascular events occurred (placebo). Baricitinib was associated with a decrease in neutrophils and increases in low-density and high-density lipoprotein.ConclusionsIn patients with rheumatoid arthritis and an inadequate response or intolerance to conventional synthetic DMARDs, baricitinib was associated with clinical improvement and inhibition of progression of radiographic joint damage.Trial registration numberNCT01721057; Results.

• Publisher: Elsevier Limited,BMJ Publishing Group
• Subject: Adult / Antirheumatic Agents - therapeutic use / Arthritis, Rheumatoid - diagnostic imaging / Arthritis, Rheumatoid - drug therapy / Azetidines - administration & dosage / Azetidines - adverse effects / Azetidines - therapeutic use / Clinical and Epidemiological Research / Double-Blind Method / Drug dosages / Female / Humans / Hypothesis testing / Janus Kinase 1 - antagonists & inhibitors / Janus Kinase 2 - antagonists & inhibitors / Kinases / Laboratories / Male / Middle Aged / Patients / Protein Kinase Inhibitors - administration & dosage / Protein Kinase Inhibitors - adverse effects / Protein Kinase Inhibitors - therapeutic use / Purines / Pyrazoles / Radiography / Retreatment / Severity of Illness Index / Sulfonamides - administration & dosage / Sulfonamides - adverse effects / Sulfonamides - therapeutic use / Tuberculosis